Clinical trials: in Mexico
Neoplasms
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the…
- Trial name
- NCT04607421
- Testing
- Encorafenib, Cetuximab, Oxaliplatin
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 841 people
- Sponsor
- Pfizer
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer.
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
- Trial name
- NCT04155034
- Testing
- Magnetic Resonance Imaging, Prophylactic Cranial Irradiation
- Where
- 446 sites in United States, Canada and 5 more
- Volunteers
- 668 people
- Sponsor
- SWOG Cancer Research Network
Major Depressive Disorder (MDD)
Transcranial Magnetic Stimulation in Depression.
Major depressive disorder (MDD) has increased in recent years, affecting 16.1% of the adult population nationwide. Currently, there are pharmacological and psychological treatments that have a 67% remission rate for depressive…
- Trial name
- LiTMS (NCT07638202)
- Testing
- The experimental group(A) received conventional drug treatment combined with Li-TMS., control group B were administered standard drug therapy with coil placement, without exposure to Li-TMS emission.
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Instituto Mexicano del Seguro Social
Bioequivalence Study in Healthy Subjects
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 850 mg Tablets Under Fed Conditions.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL24-PC019 (NCT07633028)
- Testing
- Empagliflozin/metformin 12.5/850 mg tablet (test), Synjardy 12.5/850 mg tablet (Reference)
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ADIUM
Bioequivalence Study in Healthy Subjects
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 500 mg Tablets Under Fed Conditions.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-PC016 (NCT07633054)
- Testing
- Synjardy 5/850 mg tablet, Reference, Empagliflozin/metformin 12.5/500 mg test
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ADIUM
Bioequivalence Study in Healthy Subjects
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 5 mg / 850 mg Tablets Under Fed Conditions.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL24-PC018 (NCT07633015)
- Testing
- Test. Empagliflozin/metformin 5/850 mg, Synjardy 5/850 mg tablet, Reference
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ADIUM
Bioequivalence Study in Healthy Subjects
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 1000 mg Tablets Under Fed Conditions.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL24-PC020 (NCT07633041)
- Testing
- Synjardy 12.5/1000 mg tablet, Empagliflozin/metformin 12.5/1000 mg
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ADIUM
Pulpitis
Buffered Versus Conventional Local Anesthesia for Pain and Anxiety Reduction in School-Aged Children With Pulpitis
The objective of this clinical trial is to evaluate whether buffered local anesthesia is more effective than conventional local anesthesia in reducing pain responses in school-aged children requiring dental treatment for…
- Trial name
- NCT07638254
- Testing
- Buffered Lidocaine with Epinephrine, idocaine with Epinephrine (Conventional)
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Smoldering Multiple Myeloma
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk…
- Trial name
- NCT03301220
- Testing
- Daratumumab SC: daratumumab + rHuPH20
- Where
- 163 sites in United States, Argentina and 22 more
- Volunteers
- 390 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Familial Chylomicronemia
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS).
- Trial name
- PALISADE (NCT05089084)
- Testing
- Plozasiran
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 75 people
- Sponsor
- Arrowhead Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM)
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving…
- Trial name
- NCT07628985
- Testing
- Bofanglutide, Semaglutide
- Where
- 7 sites in Mexico
- Volunteers
- 374 people
- Sponsor
- Carnot Laboratories
Coronary Artery Disease, Cognitive Impairment
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
The ISCHEMIA-HF trial will randomize participants with multivessel coronary artery disease (CAD) with ejection fraction (EF) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (GDMT):coronary artery bypass grafting…
- Conditions
- Coronary Artery Disease, Cognitive Impairment, Heart Failure
- Trial name
- ISCHEMIA-LVD (NCT06566183)
- Testing
- Guideline-directed medical therapy (GDMT), Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI).
- Where
- 6 sites in United States, Brazil and 4 more
- Volunteers
- 1,200 people
- Sponsor
- NYU Langone Health
PNH
Pegcetacoplan Long Term Safety and Efficacy Extension Study
This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
- Trial name
- NCT03531255
- Testing
- Pegcetacoplan
- Where
- 62 sites in United States, Australia and 19 more
- Volunteers
- 137 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Muscle Invasive Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative…
- Trial name
- VOLGA (NCT04960709)
- Testing
- Durvalumab, Tremelimumab, Enfortumab Vedotin
- Where
- 196 sites in United States, Argentina and 23 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
HIV-1
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs
The purpose of this study is to provide early access of TMC125 to HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens.
- Trial name
- NCT00354627
- Testing
- TMC125
- Where
- 304 sites in United States, Belgium and 14 more
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Bioequivalance
Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting Conditions
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL24-PC031 (NCT07624357)
- Testing
- Reference, Test
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ADIUM
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Ductal Adenocarcinoma
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination…
- Trial name
- NCT07076121
- Testing
- Navlimetostat, Gemcitabine, Nab-paclitaxel
- Where
- 269 sites in United States, Argentina and 34 more
- Volunteers
- 470 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.